Cellectis (NASDAQ:CLLS) Upgraded to Buy at StockNews.com

Cellectis (NASDAQ:CLLS - Get Free Report) was upgraded by equities researchers at StockNews.com from a "hold" rating to a "buy" rating in a note issued to investors on Wednesday.

Cellectis Stock Performance

Shares of CLLS traded up $0.21 during mid-day trading on Wednesday, hitting $1.44. 378,400 shares of the company traded hands, compared to its average volume of 144,156. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.78 and a current ratio of 1.78. The stock has a market cap of $80.04 million, a price-to-earnings ratio of -1.11 and a beta of 3.22. Cellectis has a 1 year low of $1.10 and a 1 year high of $3.38. The stock has a 50-day moving average price of $1.35 and a two-hundred day moving average price of $1.66.

Cellectis (NASDAQ:CLLS - Get Free Report) last issued its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.06 by ($0.22). The business had revenue of $33.22 million for the quarter, compared to the consensus estimate of $5.90 million. Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. Equities analysts anticipate that Cellectis will post -0.46 earnings per share for the current year.

Hedge Funds Weigh In On Cellectis

Hedge funds and other institutional investors have recently bought and sold shares of the company. Wells Fargo & Company MN lifted its stake in Cellectis by 103.4% in the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company's stock valued at $44,000 after buying an additional 12,500 shares during the last quarter. B Group Inc. acquired a new position in shares of Cellectis during the 4th quarter worth $5,547,000. Finally, Millennium Management LLC acquired a new position in shares of Cellectis during the 4th quarter worth approximately $962,000. 63.90% of the stock is currently owned by hedge funds and other institutional investors.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.